General information
At the Department of Toxicogenomics (TGX), a multidisciplinary team of biologists, chemists, toxicologists and bioinformaticians is working in close collaboration to establish the biological impact of exposures to potentially toxic compounds. The rapid development of the new, so called omics-technologies, has enabled us to establish responses at different molecular levels with higher sensitivity than most classical effect markers, and providing information on the involved molecular mechanisms of action. As such, toxicogenomics research combines toxicology with genomics approaches in order to obtain more accurate understanding of toxicological processes. The application of these innovative omics-technologies in in vitro toxicology and human health risk analysis can be regarded as the central research paradigm of our department.
Our Mission
The mission of Department of Toxicogenomics is to explore, develop and to exploit the full potential of innovative cell technologies and genomics platforms, for the purpose of advancing mechanism-based in vitro assays using human cells, for predictive toxicology, as well as for developing novel biomarkers of toxic exposure and effect to be used in human population studies.
Our Network
The department has strong collaborations both at the national level within the context of the Netherlands Toxicogenomics Centre, which is coordinated from our department, and at the international level in the context of numerous EU and non-EU projects. Within Maastricht University there is a long history of collaboration with various clinical departments in the Maastricht University Medical Centre (MUMC+). The Department of Toxicogenomics is part of the GROW Research School for Oncology and Developmental Biology and MHeNs School for Mental Health and Neuroscience.
Papers published in 2019
Upcoming
11th World Congress on Alternatives and Animal Use in the Life Sciences 2020 (WC11)
WC11 will be held in Maastricht, the Netherlands from 23-27 August 2020. The general theme of the congress, ‘3Rs in transition: from development to application’, emphasizes the increasing focus on the use of better, more human-relevant models for personalized and preventive health care, safer products and innovative research.
WC11 will explore the latest in 3R R&D and will provide a multidisciplinary programme covering more traditional themes as well as very latest issues and novel developments in the field of alternatives to animal testing in the life sciences.
Stay updated or submit a session for the scientific program via the official website www.wc11maastricht.org. Also subscribe for our newsletter for important news and developments.
